About
Small Molecule, Biologics
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyMidwest
Team (13)
Abby Freeman
Abby FreemanFormer Executive Vice President For Administration, Stowers Institute For Medical Research
BioMed Valley Discoveries
team_memberexecutive
Anna Groover
Anna Groover, PhDSenior Scientist, Translational Sciences
BioMed Valley Discoveries
team_member
Barry R
Barry R. Frankel, MBADirector, Business Development
BioMed Valley Discoveries
team_member
Brent L
Brent L. Kreider, PhDPresident, Biomed Valley Discoveries, Inc.
BioMed Valley Discoveries
team_member
Caroline Emery
Caroline Emery, PhDDirector, Translational Sciences
BioMed Valley Discoveries
team_member
Charles German
Charles GermanExecutive Vice President and General Counsel, Stowers Resource Management
BioMed Valley Discoveries
team_memberexecutive
Clinical Trials (19)
View allTotal Trials
19
As Lead Sponsor
10
As Collaborator
9
Total Enrollment
646
By Phase
PHASE1/PHASE2: 3PHASE2: 6PHASE1: 9EARLY_PHASE1: 1
By Status
TERMINATED: 6COMPLETED: 6RECRUITING: 5ACTIVE_NOT_RECRUITING: 2
Clinical Trials Pipeline19 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06773195Collaborator
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
PHASE1/PHASE2Recruiting
37 participants
Started: Jan 7, 2025 · Completed: Jan 31, 2028
NCT06411821Collaborator
Ulixertinib in People With Histiocytic Neoplasms
PHASE2Recruiting
38 participants
Started: May 7, 2024 · Completed: May 31, 2027
NCT05985954Collaborator
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
PHASE1Recruiting
27 participants
Started: Jan 18, 2024 · Completed: Mar 28, 2028
NCT05804227Collaborator
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
EARLY_PHASE1Recruiting
20 participants
Started: Apr 20, 2023 · Completed: Sep 22, 2027
NCT05221320Lead Sponsor
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
PHASE2Terminated
47 participants
Started: May 26, 2022 · Completed: Jul 14, 2024
Locations (1)
Headquarters
Kansas City, MO, United States
Map
Loading map...